Role of Litigation in Defining Drug Risks_JAMA / BMJ
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
-
-
Are Lipid lowering (Statins) Guidelines Evidence-Based? Lancet
The authors argue that recommendations for the expanded use of statins to stave off cardiovascular disease are NOT supported by the evidence.
-
Eli Lilly Lies About Zyprexa_NYT Editorial Calls for CongressionalHearings
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
-
Eli Lilly Documents Show Risks of Zyprexa were deliberately played down_NYT
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation." -
Flu Vaccine–where is the evidence?
This is an addendum to yesterday's Infomail in which we disseminated disinformation issued by the U.S. Center for Disease Control (CDC). www.ahrp.org/cms/content/view/396/80
-
Human Pesticide Experiments
Human Pesticide Experiments “Allowing human experiments, such as those conducted recently in the United Kingdom, to serve as the basis for registering pesticides, is ethically indefensible.” Ken Cook, President Environmental Working Group January 8, 2003 "Should the EPA Accept Human Pesticide Experiments?", testimony by Vera Hassner Sharav before the Committee…
-
Researcher To Be Sacked After Reporting High Rates of ADHD – BMJ
Researcher To Be Sacked After Reporting High Rates of ADHD – BMJ Sun, 10 Apr 2005 The BMJ reports that Dr. Gretchen LeFever, a clinical psychologist and professor at Eastern Virginia Medical School, whose published reports (since 1995) have raised the alarm about a spiraling increase in elementary school children…
-
Ethics / Science of ARDS Controversy Continues – J Medical Ethics-BMJ
Ethics / Science of ARDS Controversy Continues – J Medical Ethics-BMJ Thu, 6 Oct 2005 The ethics and science of a controversial clinical trial sponsored by the US government and conducted at multiple sites by the ARDS Network comprising of prestigious academic medical centers is the subject of a continuing…
-
Meta-Analysis: Efficacy & Safety of Antidepressants for Children – Brit Medical Journal
Meta-Analysis: Efficacy & Safety of Antidepressants for Children – Brit Medical Journal Sat, 10 Apr 2004 As news of skyrocketing prescribing of antidepressants for children–especially in preschool children–hit the news waves around the world, a major meta-analysis of the 5 published pediatric antidepressant studies was published in the British Medical…
-
British Medical Journal critized for promoting drug cocktail ignoring risks
British Medical Journal critized for promoting drug cocktail ignoring risks Mon, 14 Jul 2003 The push toward adopting a radical cholesterol lowering strategy, including the use of statin drugs was given a shot in the arm when the British Medical Journal (BMJ) published an article– endorsed by its editor–promoting the…
-
Protecting Editorial Integrity – Dr. Stefan Kreuszewski BMJ
Protecting Editorial Integrity – Dr. Stefan Kreuszewski BMJ Sun, 6 Feb 2005 In his BMJ editorial, “A tough nut to crack,” Kamran Abassi writes: “The drug industry considers the BMJ a tough nut to crack,” an insider recently told us. Publishing a “favourable” research paper is far trickier in the…
-
ADHD drug Cylert withdrawn from market due to Liver Toxicity
ADHD drug – Cylert withdrawn from market due to Liver Toxicity, a Major Risk of Psychotropic Drugs Tue, October 25, 2005 The FDA announced that another drug prescribed for ADHD–Cylert–was removed from the US market for safety reasons. On September 25, 2005, the Associated Press reported: “Eli Lilly said it…